News

A methotrexate (MTX) treatment protocol that includes the administration of glucocorticoids is superior to phototherapy in treating childhood localized scleroderma, a study found. Nonetheless, researchers suggest MTX should be used preferentially in more severe cases of the disease. The study, “Comparing ultraviolet light A photo(chemo)therapy with…

Levels of certain important signaling molecules called cytokines are associated with different clinical manifestations in patients with scleroderma, a study suggests. The study, “Different profile of cytokine production in patients with systemic sclerosis and association with clinical manifestations,” was published in the journal Immunology Letters. Cytokines are…

Rituximab (brand name Rituxan, among others) may be effective in treating patients with diffuse systemic sclerosis, according to a French retrospective study and literature review. Although there are several small-scale reports supporting rituximab as a treatment for systemic sclerosis (SSc) patients, no large-scale studies have been conducted. Researchers found it…

The occurrence of blood clots in the veins of scleroderma patients is rare and does not change patients’ survival rates, a new Canadian study shows. Still, researchers see a need for improved understanding of venous thromboembolism (VTE) in these patients. The study, “Venous Thromboembolism in Systemic Sclerosis: Prevalence,…